Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine.

Saved in:
Bibliographic Details
Title: Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine.
Authors: Janes H; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Biostatistics, University of Washington, Seattle, WA, USA., Fong Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Biostatistics, University of Washington, Seattle, WA, USA., Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Biostatistics, University of Washington, Seattle, WA, USA., Benkeser D; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA., Kelly EJ; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Hirsch I; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Stanley AM; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Villafana T; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Petropoulos CJ; LabCorp-Monogram Biosciences, South San Francisco, CA, USA., Leith A; Nexelis, Seattle, WA, USA., Haugaard D; Nexelis, Seattle, WA, USA., Webb B; Nexelis, Seattle, WA, USA., Lu Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Borate B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., van der Laan LWP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Statistics, University of Washington, Seattle, WA, USA., Hejazi NS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Biostatistics, T.H. Chan School of Public Health, Harvard University, Boston, MA, USA., Randhawa AK; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Andrasik MP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Isaacs MB; Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA., Makhene M; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Tong T; Vaccine Research Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Robb ML; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA., Neuzil KM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.; Fogarty International Center, National Institutes of Health, Bethesda, MD, USA., Follmann D; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Falsey AR; Division of Infectious Diseases, Department of Medicine, University of Rochester, Rochester, NY, USA., Sobieszczyk ME; Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY, USA., Koup RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. pgilbert@fredhutch.org.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. pgilbert@fredhutch.org.; Department of Biostatistics, University of Washington, Seattle, WA, USA. pgilbert@fredhutch.org.
Corporate Authors: AstraZeneca AZD1222 Clinical Study Group, Immune Assays Team, United States Government (USG)/CoVPN Biostatistics Team
Source: NPJ vaccines [NPJ Vaccines] 2026 Apr 18; Vol. 11 (1). Date of Electronic Publication: 2026 Apr 18.
Publication Type: Journal Article
Journal Info: Publisher: Springer Nature in partnership with the Sealy Center for Vaccine Development Country of Publication: England NLM ID: 101699863 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-0105 (Electronic) Linking ISSN: 20590105 NLM ISO Abbreviation: NPJ Vaccines Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2059-0105
DOI:10.1038/s41541-026-01411-1